课题基金 / 基金详情

Engineering the next generation of T cells

Engineering the next generation of T cells
设计下一代 T 细胞
批准号:
10064451
负责人:
CARL H. JUNE
金额:
$23.31万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2019
资助国家:
美国
项目状态:
已结题
起止时间:
2019-09-25 至 2024-08-31

项目摘要

项目成果

CARL H. JUNE的其他基金

相似基金

相关文献

中文摘要
翻译
这个U54“免疫工程以改进免疫治疗(I3)中心”是在 响应RFA-CA-19-013。U54的目的是应用免疫工程学 设计更持久、更容易获得和毒性更低的免疫预防和 免疫治疗策略。癌症登月计划设定的一个国家优先事项是支持 研究融合了下一代基因工程、工程生物材料、 纳米技术,计算和数学模型,或系统生物学方法 重点关注下一代免疫疗法的设计、实施和评估 克服免疫抑制障碍,靶向杀伤肿瘤细胞,并产生Long 持久的抗癌免疫记忆。我们的U54题为《设计下一个》的重点 T细胞的产生“是关于发展下一代的基因编辑或免疫修饰 细胞在体内提高持久性,控制和操纵免疫系统以减少脱靶 过继细胞治疗的毒性和增强抗肿瘤效果。我们的中央 假设下一代工程可以提高CAR T细胞的安全性和有效性 同时降低了商品的成本。 我们的U54中心有三个科学项目。这些项目的共同目标是 使这一强大的疗法能够覆盖更广泛的血癌和固体癌症患者 癌症。在项目1中,我们正在使用CRISPR/Cas9编辑T细胞的表观基因组,并制作 抵抗细胞因子释放综合征(CRS)的细胞,同时利用工程技术 自动化CAR T细胞培养。项目2的目标是生成通用CAR T细胞(UCART) 使用先进的基因编辑技术,然后将UCAR与自体CAR进行比较 一种独特的犬癌模型。在项目3中,我们将使用先进的蛋白质工程,细胞 用于检测人工合成的细胞因子和细胞因子受体系统的工程和溶瘤载体 小鼠和人类T细胞,长期目标是消除或减少对 过继细胞移植前的淋巴耗竭调节化疗。我们的方法是 多学科、多机构。我们汇聚了一支杰出的干部队伍 来自多个学科的研究人员,他们合作并共同发表了许多 好几年了。使用CRISPR/Cas9和细胞培养技术进行最先进的基因编辑 宾夕法尼亚大学与世界级蛋白质工程和 斯坦福大学结构生物学。每个项目都由该领域公认的权威机构领导。 该U54的管理核心旨在管理和协调所有i3中心研究 项目活动,并担任i3中心和物联网数据管理之间的联络人 和资源共享中心(U24)和其他癌症登月联盟,包括儿科 免疫疗法发现和发展网络(PI-DDN)。此外,行政部门 CORE将协调i3中心研究项目之间的协作研究活动 PD(S)/PI(S)和IOTN(或其他)调查人员。范式转换的潜在影响本U54 是将第一代CAR T治疗白血病和淋巴瘤的教训转化为有意义的 对所有恶性肿瘤的疗效。
英文摘要
This U54 “Immuno-engineering to improve Immunotherapy (i3) Center” was developed in response to RFA-CA-19-013. The purpose of this U54 is to employ immune-engineering principles to design more durable, accessible, and less toxic immunoprevention and immunotherapy strategies. A national priority set by the cancer Moonshot initiative is to support studies incorporating next-generation genetic engineering, engineered biomaterials, nanotechnology, computational and mathematical modelling, or systems biology approaches in design, implementation and evaluation of next generation immunotherapies focused on overcoming immunosuppressive barriers, targeting tumor cells for killing, and generating long lasting anti-cancer immunological memory. The focus of our U54 entitled “Engineering the Next Generation of T cells” is on developing next-generation gene-editing or modification of immune cells to improve persistence in vivo, control and manipulate the immune system to reduce offtarget toxicities and enhance anti-tumor effectiveness of adoptive cell therapy. Our central hypothesis is that next generation engineering can improve the safety and efficacy of CAR T cells while decreasing the cost of goods. There are three scientific projects in our U54 Center. The shared goal of these projects is to enable this powerful therapy to reach a broader spectrum of patients with blood cancer and solid cancers. In Project 1, we are using CRISPR/Cas9 to edit the epigenome of T cells and to make cells resistant to cytokine release syndrome (CRS), while employing engineering technologies to automate CAR T cell culture. The goal of Project 2 is to generate universal CAR T cells (UCART) using advanced genetic editing technologies and then to compare UCAR to autologous CAR T in a unique model of canine cancer. In Project 3 we will use advanced protein engineering, cell engineering and oncolytic vectors to test synthetic cytokine and cytokine receptor systems in mouse and human T cells, with the long-term goal of eliminating or reducing the need for lymphodepleting conditioning chemotherapy prior to adoptive cell transfer. Our approach is multidisciplinary and multi- institutional. We have brought together a cadre of exceptional investigators from multiple disciplines who have collaborated and published together for many years. State of the art genetic editing with CRISPR/Cas9 and cell culture technologies at the University of Pennsylvania are synergistically coupled with world-class protein engineering and structural biology at Stanford University. Each project is led by recognized authorities in the field. The Administrative Core for this U54 is designed to manage and coordinate all i3 Center Research Project activities and serve as the liaison between the i3 Center and the IOTN Data Management and Resource-sharing Center (U24) and other Cancer Moonshot consortia, including the Pediatric Immunotherapy Discovery and Development Network (PI-DDN). In addition, the Administrative Core will coordinate collaborative research activities between the i3 Center Research Project PD(s)/PI(s) and IOTN (or other) investigators. The potential for paradigm-shifting impact this U54 is to transform the lessons of first-generation CAR T for leukemia and lymphoma into meaningful efficacy against all malignancies.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Engineering the Next Generation of T Cells
  • 批准号:
    10578324
  • 项目类别:
  • 资助金额:
    $24.38万
  • 财政年份:
    2019
  • 负责人:
    CARL H. JUNE
  • 依托单位:
Directing the metabolic fate of CAR T cells
  • 批准号:
    10364746
  • 项目类别:
  • 资助金额:
    $42.37万
  • 财政年份:
    2018
  • 负责人:
    CARL H. JUNE
  • 依托单位:
Enhancing Chimeric Antigen Receptor T Cell Therapies for HematologicMalignancies: Beyond CART 19
  • 批准号:
    10713199
  • 项目类别:
  • 资助金额:
    $278.23万
  • 财政年份:
    2017
  • 负责人:
    CARL H. JUNE
  • 依托单位:
Project 2: Towards a safe and effective AML treatment strategy using anti-CD33 CAR T cells in combination with CAR-resistant hematopoietic stem cells
  • 批准号:
    10245064
  • 项目类别:
  • 资助金额:
    $31.74万
  • 财政年份:
    2017
  • 负责人:
    CARL H. JUNE
  • 依托单位:
海外基金